Main Management Fund Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Main Management Fund Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-598,200	Closed	-$55.5M	–	7
2024 Q2	$55.5M	Buy	598,200 +45,700	+8%	+$4.1M	9.99%	4
2024 Q1	$52.4M	Buy	552,500 +81,000	+17%	+$7.52M	10.66%	3
2023 Q4	$42.1M	Buy	471,500 +190,500	+68%	+$14.1M	11.79%	2
2023 Q3	$20.5M	Buy	281,000 +37,500	+15%	+$3M	5.97%	7
2023 Q2	$20.3M	Buy	243,500 +45,200	+23%	+$3.78M	6.53%	7
2023 Q1	$15.1M	Buy	198,300 +28,300	+17%	+$2.35M	6.59%	7
2022 Q4	$14.1M	Buy	170,000 +10,600	+7%	+$858K	8.9%	7
2022 Q3	$12.6M	Buy	159,400 +10,500	+7%	+$885K	9.08%	5
2022 Q2	$11.1M	Buy	148,900 +83,500	+128%	+$6.27M	7.82%	5
2022 Q1	$5.88M	Buy	+65,400	New	+$6.04M	3.8%	7

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Main Management Fund Advisors's XBI Position: Q3 2024 in Review

Main Management Fund Advisors sold out of State Street SPDR S&P Biotech ETF (XBI) in Q3 2024, closing a stake of 598,200 shares — an estimated $55.5M sold.

Main Management Fund Advisors first reported a position in XBI in Q1 2022 and held it in 10 quarters. The position peaked at $55.5M in Q2 2024. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

Main Management Fund Advisors reported no remaining State Street SPDR S&P Biotech ETF position as of Q3 2024 after selling out during the quarter.
Main Management Fund Advisors sold 598,200 State Street SPDR S&P Biotech ETF shares in Q3 2024, an estimated $55.5M.
Main Management Fund Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and held it in 10 quarters.
Main Management Fund Advisors's State Street SPDR S&P Biotech ETF position peaked at $55.5M in Q2 2024.
769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Main Management Fund Advisors's 13F filing for Q3 2024, filed 15 Nov 2024.